Enhances biologic therapeutics testing services
SGS (formerly Société Générale de Surveillance) has acquired Glasgow-based contract testing organisation Vitrology to add to its biologic therapeutics testing services.
No financial details were revealed.
The Swiss multinational inspection, testing and certification firm will add Vitrology’s GLP/cGMP laboratory in Clydebank, its 38 staff and sales agents in the US and Asia to its business.
Vitrology, founded in 2007, provides a range of biosafety services including virology, cell and molecular biology as well as microbiology and electron microscopy.
Chris Kirk, chief executive of SGS, said the acquisition builds on the firm’s biologic therapeutics strategy and complements the services provided by SGS.
‘It creates an ideal platform for further deployment in virology and molecular biology activities, to be leveraged within our global network,’ he said.
Margaret Temple, ceo of Vitrology, added: ‘This is an exciting opportunity to provide a full service offer across Europe, Americas and Asia focused on biologics and vaccines, and enhances SGS’s current portfolio in bioanalysis, cell-based and immunoassays, quality control and Phase I to IV clinical trial services.’
The deal takes SGS’s Life Science Services global network to 19 laboratories.
SGS employs more than 70,000 people and operates a network of more than 1,350 offices and laboratories around the world.